Palatin Technologies (NYSEAMERICAN:PTN – Get Free Report) issued its earnings results on Monday. The company reported ($1.29) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.58), reports. The firm had revenue of $0.36 million during the quarter, compared to the consensus estimate of $1.79 million.
Palatin Technologies Stock Performance
Shares of PTN stock traded down $0.01 on Wednesday, hitting $5.35. 5,466 shares of the stock traded hands, compared to its average volume of 35,372. The company’s fifty day moving average is $7.93 and its 200 day moving average is $13.39. Palatin Technologies has a 1-year low of $4.51 and a 1-year high of $31.00.
Palatin Technologies Company Profile
Palatin Technologies is a biopharmaceutical company focused on developing medicines that target melanocortin receptors, which are involved in processes such as inflammation, immune response and appetite regulation. Its research has included peptide-based treatments for inflammatory and other medical conditions. The company is best known for developing bremelanotide, marketed as Vyleesi, which the U.S. Food and Drug Administration approved in 2019 to treat acquired, generalized hypoactive sexual desire disorder in premenopausal women.
See Also
- Five stocks we like better than Palatin Technologies
- 5 Consumer Discretionary Plays Showing Strength During the Tech Sell-Off
- NVIDIA’s Earnings Were Strong, But Can the Next CEO Keep the Momentum Going?
- SpaceX’s Historic Starship Catch Raises a Bigger Question About Its AI Spending
- AMD Bets $8.2B on Physical AI: Could Robotics Be Its Next Growth Frontier?
Receive News & Ratings for Palatin Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palatin Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
